Head & Neck trials now recruiting
TROG 12.01 (HPV) - this study aims to compare radiotherapy combined with either cetuximab or cisplatin in patients with locoregionally advanced HPV positive oropharyngeal squamous cell carcinoma (OPSCC) (located at the base of tongue or tonsil).
Primary sponsor: TROG
|